Terence A Ketter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/63373/publications.pdf

Version: 2024-02-01

189 papers 13,424 citations

53 h-index 22764 112 g-index

195 all docs

195
docs citations

195 times ranked 7552 citing authors

#	Article	IF	Citations
1	Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. NeuroReport, 1995, 6, 1853-1856.	0.6	834
2	Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. New England Journal of Medicine, 2007, 356, 1711-1722.	13.9	822
3	Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. Archives of General Psychiatry, 2003, 60, 1079.	13.8	797
4	A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. American Journal of Psychiatry, 2005, 162, 1351-1360.	4.0	790
5	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	4.0	579
6	Predictors of Recurrence in Bipolar Disorder: Primary Outcomes From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry, 2006, 163, 217-224.	4.0	563
7	Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry, 2003, 53, 1028-1042.	0.7	493
8	The Increasing Use of Polypharmacotherapy for Refractory Mood Disorders. Journal of Clinical Psychiatry, 2000, 61, 9-15.	1.1	415
9	A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders. Journal of Clinical Psychopharmacology, 2000, 20, 607-614.	0.7	385
10	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Extended-Release Carbamazepine Capsules as Monotherapy for Bipolar Disorder Patients With Manic or Mixed Episodes. Journal of Clinical Psychiatry, 2004, 65, 478-484.	1.1	331
11	The Texas Implementation of Medication Algorithms. Journal of Clinical Psychiatry, 2005, 66, 870-886.	1.1	296
12	Olanzapine Versus Divalproex Sodium for the Treatment of Acute Mania and Maintenance of Remission: A 47-Week Study. American Journal of Psychiatry, 2003, 160, 1263-1271.	4.0	294
13	Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biological Psychiatry, 2000, 47, 475-481.	0.7	278
14	Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biological Psychiatry, 2001, 49, 97-109.	0.7	275
15	Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biological Psychiatry, 2002, 51, 237-252.	0.7	267
16	Treatment-Resistant Bipolar Depression: A STEP-BD Equipoise Randomized Effectiveness Trial of Antidepressant Augmentation With Lamotrigine, Inositol, or Risperidone. American Journal of Psychiatry, 2006, 163, 210-216.	4.0	218
17	Treating insomnia improves mood state, sleep, and functioning in bipolar disorder: A pilot randomized controlled trial Journal of Consulting and Clinical Psychology, 2015, 83, 564-577.	1.6	196
18	Regional cerebral metabolism associated with anxiety symptoms in affective disorder patients. Biological Psychiatry, 2000, 48, 1020-1023.	0.7	175

#	Article	IF	CITATIONS
19	The prevalence and burden of bipolar depression. Journal of Affective Disorders, 2014, 169, S3-S11.	2.0	156
20	Stabilization of Mood From Below Versus Above Baseline in Bipolar Disorder. Journal of Clinical Psychiatry, 2002, 63, 146-151.	1.1	148
21	Extended-Release Carbamazepine Capsules as Monotherapy for Acute Mania in Bipolar Disorder. Journal of Clinical Psychiatry, 2005, 66, 323-330.	1.1	148
22	Temperamental commonalities and differences in euthymic mood disorder patients, creative controls, and healthy controls. Journal of Affective Disorders, 2005, 85, 207-215.	2.0	144
23	The Emerging Role of Cytochrome P450 3A in Psychopharmacology. Journal of Clinical Psychopharmacology, 1995, 15, 387-398.	0.7	144
24	Depressive Illness Burden Associated With Complex Polypharmacy in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2009, 70, 155-162.	1.1	130
25	Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Research, 1993, 49, 257-272.	1.7	129
26	Sleep functioning in relation to mood, function, and quality of life at entry to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Journal of Affective Disorders, 2009, 114, 41-49.	2.0	117
27	Enhanced creativity in bipolar disorder patients: A controlled study. Journal of Affective Disorders, 2007, 100, 31-39.	2.0	113
28	Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disorders, 2004, 6, 460-469.	1.1	110
29	Sleep matters: Sleep functioning and course of illness in bipolar disorder. Journal of Affective Disorders, 2011, 134, 416-420.	2.0	109
30	Potential Mechanisms of Action of Lamotrigine in the Treatment of Bipolar Disorders. Journal of Clinical Psychopharmacology, 2003, 23, 484-495.	0.7	105
31	Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biological Psychiatry, 2002, 51, 253-260.	0.7	97
32	Adjunctive Armodafinil for Major Depressive Episodes Associated With Bipolar I Disorder. Journal of Clinical Psychiatry, 2010, 71, 1363-1370.	1.1	96
33	Functional Brain Imaging, Limbic Function, and Affective Disorders. Neuroscientist, 1996, 2, 55-65.	2.6	89
34	Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?. Journal of Affective Disorders, 2002, 69, 1-14.	2.0	86
35	Nimodipine Monotherapy and Carbamazepine Augmentation in Patients With Refractory Recurrent Affective Illness. Journal of Clinical Psychopharmacology, 1998, 18, 404-413.	0.7	86
36	Decreased prefrontal, anterior cingulate, insula, and ventral striatal metabolism in medication-free depressed outpatients with bipolar disorder. Journal of Psychiatric Research, 2009, 43, 181-188.	1.5	85

#	Article	lF	Citations
37	Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar <scp>CHOICE</scp>). Bipolar Disorders, 2015, 17, 212-223.	1.1	77
38	Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. Journal of Affective Disorders, 2013, 151, 722-727.	2.0	76
39	Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. Biological Psychiatry, 1999, 46, 1364-1374.	0.7	73
40	Temperament–creativity relationships in mood disorder patients, healthy controls and highly creative individuals. Journal of Affective Disorders, 2007, 100, 41-48.	2.0	72
41	Psychotic bipolar disorders: dimensionally similar to or categorically different from schizophrenia?. Journal of Psychiatric Research, 2004, 38, 47-61.	1.5	71
42	Differential Efficacy of Olanzapine and Lithium in Preventing Manic or Mixed Recurrence in Patients With Bipolar I Disorder Based on Number of Previous Manic or Mixed Episodes. Journal of Clinical Psychiatry, 2006, 67, 95-101.	1.1	70
43	Impact of Lamotrigine and Lithium on Weight in Obese and Nonobese Patients With Bipolar I Disorder. American Journal of Psychiatry, 2006, 163, 1199-1201.	4.0	69
44	Recurrence rates in bipolar disorder: Systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials. European Neuropsychopharmacology, 2015, 25, 1501-1512.	0.3	69
45	Sleep, residual mood symptoms, and time to relapse in recovered patients with bipolar disorder. Journal of Affective Disorders, 2016, 190, 162-166.	2.0	69
46	Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness). Journal of Clinical Psychiatry, 2016, 77, 90-99.	1.1	69
47	Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disorders, 2006, 8, 175-181.	1.1	65
48	Poor quality of life and functioning in bipolar disorder. International Journal of Bipolar Disorders, 2017, 5, 10.	0.8	63
49	Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar) Tj ETQq1 1 0.7	84314 rg	BT /Overlock 60
50	Metabolism and excretion of mood stabilizers and new anticonvulsants. Cellular and Molecular Neurobiology, 1999, 19, 511-532.	1.7	59
51	Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 2014, 155, 20-27.	2.0	58
52	LURASIDONE IN THE LONGâ€TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24â€WEEK OPENâ€L EXTENSION STUDY. Depression and Anxiety, 2016, 33, 424-434.	ABEL 2.0	58
53	A 6-Month, Multicenter, Open-Label Evaluation of Beaded, Extended-Release Carbamazepine Capsule Monotherapy in Bipolar Disorder Patients With Manic or Mixed Episodes. Journal of Clinical Psychiatry, 2004, 65, 668-673.	1.1	58
54	Overweight and obesity in bipolar disorders. Journal of Psychiatric Research, 2006, 40, 762-764.	1.5	56

#	Article	IF	CITATIONS
55	Magnetic resonance spectroscopic measurement of cerebral gamma-aminobutyric acid concentrations in patients with bipolar disorders. Acta Neuropsychiatrica, 2006, 18, 120-126.	1.0	55
56	Thirty Years of Clinical Experience with Carbamazepine in the Treatment of Bipolar Illness. CNS Drugs, 2007, 21, 47-71.	2.7	53
57	Adjunctive Aripiprazole in Treatment-Resistant Bipolar Depression. Annals of Clinical Psychiatry, 2006, 18, 169-172.	0.6	50
58	Toward interaction of affective and cognitive contributors to creativity in bipolar disorders: A controlled study. Journal of Affective Disorders, 2010, 125, 27-34.	2.0	48
59	Aripiprazole in combination with lamotrigine for the longâ€term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, doubleâ€blind study (CN138â€392). Bipolar Disorders, 2012, 14, 41-53.	1.1	48
60	Dermatology Precautions and Slower Titration Yield Low Incidence of Lamotrigine Treatment-Emergent Rash. Journal of Clinical Psychiatry, 2005, 66, 642-645.	1.1	44
61	Efficacy and Safety of Adjunctive Armodafinil in Adults With Major Depressive Episodes Associated With Bipolar I Disorder. Journal of Clinical Psychiatry, 2014, 75, 1054-1061.	1.1	43
62	Differential abnormalities of functional connectivity of the amygdala and hippocampus in unipolar and bipolar affective disorders. Journal of Affective Disorders, 2014, 168, 243-253.	2.0	42
63	Balancing benefits and harms of treatments for acute bipolar depression. Journal of Affective Disorders, 2014, 169, S24-S33.	2.0	41
64	Childhood-compared to adolescent-onset bipolar disorder has more statistically significant clinical correlates. Journal of Affective Disorders, 2015, 179, 114-120.	2.0	40
65	American tertiary clinic-referred bipolar II disorder compared to bipolar I disorder: More severe in multiple ways, but less severe in a few other ways. Journal of Affective Disorders, 2015, 188, 257-262.	2.0	40
66	Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. Journal of Affective Disorders, 2016, 191, 256-273.	2.0	40
67	Synergy of Carbamazepine and. Journal of Clinical Psychopharmacology, 1992, 12, 276???281.	0.7	38
68	Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Current Medical Research and Opinion, 2006, 22, 2345-2353.	0.9	38
69	Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000–2011. Journal of Affective Disorders, 2014, 155, 283-287.	2.0	33
70	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2015, 71, 126-133.	1.5	32
71	Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. Journal of Affective Disorders, 2015, 181, 87-91.	2.0	31
72	Lifetime presence of psychotic symptoms in bipolar disorder is associated with less favorable socio-demographic and certain clinical features. Comprehensive Psychiatry, 2017, 76, 169-176.	1.5	29

#	Article	IF	CITATIONS
73	Has Bipolar Disorder become a predominantly female gender related condition? Analysis of recently published large sample studies. International Journal of Bipolar Disorders, 2021, 9, 3.	0.8	29
74	Carbamazepine-Induced Increases in Total Serum Cholesterol. Journal of Clinical Psychopharmacology, 1992, 12, 431???437.	0.7	28
75	First controlled treatment trial of bipolar II hypomania with mixed symptoms: Quetiapine versus placebo. Journal of Affective Disorders, 2013, 150, 37-43.	2.0	28
76	Neural responses to monetary incentives in bipolar disorder. Neurolmage: Clinical, 2019, 24, 102018.	1.4	28
77	Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. Journal of Psychiatric Research, 2010, 44, 8-14.	1.5	27
78	Subjective versus objective evening chronotypes in bipolar disorder. Journal of Affective Disorders, 2018, 225, 342-349.	2.0	27
79	Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments. International Journal of Bipolar Disorders, 2015, 3, 34.	0.8	26
80	The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. Journal of Affective Disorders, 2018, 225, 350-356.	2.0	26
81	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. Journal of Affective Disorders, 2019, 257, 17-22.	2.0	26
82	Onset polarity in bipolar disorder: A strong association between first depressive episode and suicide attempts. Journal of Affective Disorders, 2017, 209, 182-187.	2.0	25
83	Special issues in the treatment of paediatric bipolar disorder. Expert Opinion on Pharmacotherapy, 2001, 2, 613-622.	0.9	24
84	Ketamine: stimulating antidepressant treatment?. BJPsych Open, 2016, 2, e5-e9.	0.3	24
85	The diverse roles of anticonvulsants in bipolar disorders. Annals of Clinical Psychiatry, 2003, 15, 95-108.	0.6	24
86	New Developments in the Use of Anticonvulsants as Mood Stabilizers. Neuropsychobiology, 1993, 27, 132-137.	0.9	23
87	The Link Between Bipolar Disorders and Creativity: Evidence from Personality and Temperament Studies. Current Psychiatry Reports, 2010, 12, 522-530.	2.1	23
88	Age at onset in patients with bipolar I and II disorder: a comparison of large sample studies. Journal of Affective Disorders, 2016, 201, 57-63.	2.0	23
89	The Effect of Dermatologic Precautions on the Incidence of Rash With Addition of Lamotrigine in the Treatment of Bipolar I Disorder. Journal of Clinical Psychiatry, 2006, 67, 400-406.	1.1	23
90	Clinical Relevance of Treatments for Acute Bipolar Disorder: Balancing Therapeutic and Adverse Effects. Clinical Therapeutics, 2011, 33, B40-B48.	1.1	22

#	Article	IF	Citations
91	Different characteristics associated with suicide attempts among bipolar I versus bipolar II disorder patients. Journal of Psychiatric Research, 2016, 76, 94-100.	1.5	22
92	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. Journal of Affective Disorders, 2016, 192, 212-218.	2.0	22
93	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2017, 51, 355-365.	1.3	22
94	Abnormal sleep duration associated with hastened depressive recurrence in bipolar disorder. Journal of Affective Disorders, 2017, 218, 374-379.	2.0	22
95	Strategies for Monitoring Outcomes in Patients With Bipolar Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2010, 12, 10-16.	0.6	22
96	Effectiveness of lamotrigine in bipolar disorder in a clinical setting. Journal of Psychiatric Research, 2008, 43, 13-23.	1.5	21
97	Psychotherapy use in bipolar disorder: Association with functioning and illness severity. Australian and New Zealand Journal of Psychiatry, 2015, 49, 453-461.	1.3	21
98	Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis. Journal of Psychiatric Research, 2017, 88, 38-46.	1.5	21
99	Italian Bipolar II vs I patients have better individual functioning, in spite of overall similar illness severity. CNS Spectrums, 2017, 22, 325-332.	0.7	21
100	Electronic Ecological Momentary Assessment (EMA) in youth with bipolar disorder: Demographic and clinical predictors of electronic EMA adherence. Journal of Psychiatric Research, 2019, 116, 14-18.	1.5	21
101	Obesity and obstetric complications are associated with rapid-cycling in Italian patients with bipolar disorder. Journal of Affective Disorders, 2017, 208, 278-283.	2.0	20
102	More inclusive bipolar mixed depression definition by permitting overlapping and nonâ€overlapping mood elevation symptoms. Acta Psychiatrica Scandinavica, 2016, 134, 199-206.	2.2	19
103	Clinical correlates of acute bipolar depressive episode with psychosis. Journal of Affective Disorders, 2017, 217, 29-33.	2.0	19
104	Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania. Journal of Affective Disorders, 2007, 100, S45-S53.	2.0	18
105	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. Journal of Affective Disorders, 2014, 161, 30-35.	2.0	18
106	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. Journal of Affective Disorders, 2017, 223, 146-152.	2.0	18
107	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. Journal of Affective Disorders, 2018, 225, 563-568.	2.0	18
108	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	1.3	18

#	Article	IF	Citations
109	Nosology, Diagnostic Challenges, and Unmet Needs in Managing Bipolar Disorder. Journal of Clinical Psychiatry, 2010, 71, e27.	1.1	17
110	Post-dexamethasone cortisol correlates with severity of depression before and during carbamazepine treatment in women but not men. Acta Psychiatrica Scandinavica, 2001, 104, 397-401.	2.2	16
111	Differentiating multiple vs single lifetime suicide attempters with bipolar disorders: A retrospective study. Comprehensive Psychiatry, 2018, 80, 214-222.	1.5	15
112	Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. Journal of Clinical Psychiatry, 2008, 69 Suppl 5, 9-15.	1.1	14
113	Blood levels of brain derived neurotrophic factor in women with bipolar disorder and healthy control women. Journal of Affective Disorders, 2014, 156, 214-218.	2.0	13
114	Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study. Journal of Affective Disorders, 2016, 197, 51-57.	2.0	13
115	Lifetime eating disorder comorbidity associated with delayed depressive recovery in bipolar disorder. International Journal of Bipolar Disorders, 2017, 5, 25.	0.8	13
116	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. Journal of Affective Disorders, 2019, 259, 164-172.	2.0	13
117	The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. Journal of Affective Disorders, 2020, 266, 772-781.	2.0	13
118	A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. Journal of Clinical Psychiatry, 2020, 81, .	1.1	13
119	Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. Journal of Clinical Psychiatry, 2002, 63 Suppl 3, 21-5.	1.1	13
120	Neuroimaging studies of bipolar depression: functional neuropathology, treatment effects, and predictors of clinical response. Clinical Neuroscience Research, 2002, 2, 182-192.	0.8	12
121	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. Depression and Anxiety, 2017, 34, 281-290.	2.0	12
122	Combination Therapy Versus Monotherapy for Bipolar Disorder. Journal of Clinical Psychiatry, 2008, 69, e34.	1.1	12
123	Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. Journal of Affective Disorders, 2015, 186, 376-382.	2.0	11
124	Current irritability robustly related to current and prior anxiety in bipolar disorder. Journal of Psychiatric Research, 2016, 79, 101-107.	1.5	11
125	More inclusive bipolar mixed depression definitions by requiring fewer nonâ€overlapping mood elevation symptoms. Acta Psychiatrica Scandinavica, 2016, 134, 189-198.	2.2	11
126	Daytime midpoint as a digital biomarker for chronotype in bipolar disorder. Journal of Affective Disorders, 2018, 241, 586-591.	2.0	11

#	Article	IF	Citations
127	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. Journal of Affective Disorders, 2019, 246, 126-131.	2.0	11
128	Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders. Bipolar Disorders, 2002, 4, 328-334.	1.1	10
129	Gender by onset age interaction may characterize distinct phenotypic subgroups in bipolar patients. Journal of Psychiatric Research, 2016, 76, 128-135.	1.5	10
130	Bipolar mixed features – Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq0 0	0 rgBT /Ov 2.0	erlock 10 Tf 5
131	American tertiary clinic-referred bipolar II disorder versus bipolar I disorder associated with hastened depressive recurrence. International Journal of Bipolar Disorders, 2017, 5, 2.	0.8	10
132	Lifetime anxiety disorder and current anxiety symptoms associated with hastened depressive recurrence in bipolar disorder. Journal of Affective Disorders, 2017, 219, 165-171.	2.0	10
133	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. Acta Neuropsychiatrica, 2018, 30, 297-305.	1.0	10
134	Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacology Bulletin, 2006, 39, 120-46.	0.0	10
135	Biology and recent brain imaging studies in affective psychoses. Current Psychiatry Reports, 2000, 2, 298-304.	2.1	9
136	Higher prevalence of bipolar I disorder among Asian and Latino compared to Caucasian patients receiving treatment. Asia-Pacific Psychiatry, 2010, 2, 156-165.	1.2	9
137	A novel application of the <i>Intent to Attend</i> assessment to reduce bias due to missing data in a randomized controlled clinical trial. Clinical Trials, 2014, 11, 494-502.	0.7	9
138	Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder. Journal of Affective Disorders, 2017, 207, 384-392.	2.0	9
139	Definition of the term "mood stabilizerâ€. Bipolar Disorders, 2018, 20, 74-75.	1.1	9
140	Episode accumulation associated with hastened recurrence and delayed recovery in bipolar disorder. Journal of Affective Disorders, 2018, 227, 657-664.	2.0	9
141	Treatment outcomes of acute bipolar depressive episode with psychosis. Depression and Anxiety, 2018, 35, 402-410.	2.0	9
142	Differential core pharmacotherapy in bipolar I versus bipolar II disorder and European versus American patients not in a syndromal episode. International Clinical Psychopharmacology, 2020, 35, 8-18.	0.9	9
143	Childhood trauma and treatment outcomes during moodâ€stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. Acta Psychiatrica Scandinavica, 2022, 145, 615-627.	2.2	9
144	Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting. Journal of Psychiatric Research, 2010, 44, 921-929.	1.5	8

#	Article	lF	CITATIONS
145	Current irritability associated with hastened depressive recurrence and delayed depressive recovery in bipolar disorder. International Journal of Bipolar Disorders, 2016, 4, 15.	0.8	8
146	Clinical characterization of Italian suicide attempters with bipolar disorder. CNS Spectrums, 2018, 23, 271-277.	0.7	8
147	Clinical characteristics of bipolar disorder: a comparative study between Argentina and the United States. International Journal of Bipolar Disorders, 2015, 3, 8.	0.8	7
148	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. Journal of Affective Disorders, 2016, 205, 159-164.	2.0	7
149	Longer-Term Effectiveness and Tolerability of Adjunctive Open Lurasidone in Patients With Bipolar Disorder. Journal of Clinical Psychopharmacology, 2018, 38, 207-211.	0.7	7
150	Anxiety disorders anticipate the diagnosis of bipolar disorder in comorbid patients: Findings from an Italian tertiary clinic. Journal of Affective Disorders, 2019, 257, 376-381.	2.0	7
151	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. Journal of Affective Disorders, 2020, 273, 131-137.	2.0	7
152	The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. Journal of Clinical Psychiatry, 2003, 64 Suppl 3, 15-20.	1.1	7
153	Bipolar Therapeutics Update 2014: A Tale of 3 Treatments. Journal of Clinical Psychiatry, 2015, 76, 69-70.	1.1	6
154	Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. Journal of Affective Disorders, 2022, 300, 41-49.	2.0	6
155	Depressed Subjects Have Decreased rCBF Activation During Facial Emotion Recognition. CNS Spectrums, 1997, 2, 45-55.	0.7	5
156	Treating Bipolar Disorder. Journal of Clinical Psychiatry, 2009, 70, e42.	1.1	5
157	Sleep Matters: Sleep Functioning and Course of Illness in Bipolar Disorder. Focus (American) Tj ETQq1 1 0.784314	1 rgBT /Ον 6.4	erlock 10 Tf
158	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. Bipolar Disorders, 2018, 21, 350-360.	1.1	5
159	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. Depression and Anxiety, 2021, 38, 114-123.	2.0	5
160	Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. Journal of Psychiatric Research, 2021, 140, 205-213.	1.5	5
161	The Emerging Role of Olanzapine in Bipolar Disorders. Psychiatric Annals, 2002, 32, 753-762.	0.1	5
162	Acute and Maintenance Treatments for Bipolar Depression. Journal of Clinical Psychiatry, 2014, 75, e10.	1.1	5

#	Article	IF	Citations
163	Strategies for the Early Recognition of Bipolar Disorder. Journal of Clinical Psychiatry, 2011, 72, e22.	1.1	5
164	Differential prevalence and demographic and clinical correlates of second-generation antipsychotic use in bipolar I versus bipolar II disorder. Journal of Psychiatric Research, 2016, 76, 52-58.	1.5	4
165	Antidepressants have complex associations with longitudinal depressive burden in bipolar disorder. Journal of Affective Disorders, 2019, 246, 836-842.	2.0	4
166	Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients. Journal of Affective Disorders, 2012, 137, 139-145.	2.0	3
167	Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients. Journal of Psychiatric Research, 2012, 46, 920-926.	1.5	3
168	Differential prevalence and demographic and clinical correlates of antidepressant use in American bipolar I versus bipolar II disorder patients. Journal of Affective Disorders, 2018, 234, 74-79.	2.0	3
169	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. Australian and New Zealand Journal of Psychiatry, 2018, 52, 994-1002.	1.3	3
170	Suicide attempts and clinical correlates in patients with bipolar I vs II disorder. European Psychiatry, 2018, 52, 113-115.	0.1	3
171	Incorporating Trial Data Into Bipolar Disorder Management. Journal of Clinical Psychiatry, 2008, 69, e21.	1.1	3
172	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. Australian and New Zealand Journal of Psychiatry, 2023, 57, 93-103.	1.3	3
173	Advances in the diagnosis and treatment of bipolar depression. Journal of Affective Disorders, 2014, 169, S1-S2.	2.0	2
174	Recognizing the Extent of Overlap Between Bipolar Disorder and Anxiety Disorders. EBioMedicine, 2015, 2, 1284-1285.	2.7	2
175	Pharmacotherapy for bipolar depression: comparative efficacy and acceptability is in the eye of the beholder. Evidence-Based Mental Health, 2015, 18, 88-88.	2.2	2
176	NNT and NNH remain helpful in evidence-based medicine. British Journal of Psychiatry, 2016, 209, 262-263.	1.7	2
177	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. Acta Neuropsychiatrica, 2019, 31, 230-234.	1.0	2
178	Clinical features and patterns of psychopharmacological prescription in bipolar patients with vs without anxiety disorders at onset. Microbial Biotechnology, 2020, 14, 714-722.	0.9	2
179	Antidepressants in bipolar disorder: Analysis of correlates overall, and in BD-I and BD-II subsamples. Journal of Affective Disorders, 2021, 292, 352-358.	2.0	2
180	Introduction $\hat{a}\in$ " Advancing understanding of the effectiveness of quetiapine in acute mania. Journal of Affective Disorders, 2007, 100, S1-S3.	2.0	1

#	Article	IF	CITATIONS
181	Postâ€dexamethasone cortisol correlates†with severity of depression before and†during carbamazepine treatment in women but not men. Acta Psychiatrica Scandinavica, 2001, 104, 397-401.	2.2	1
182	Commentary on the Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. American Journal of Psychiatry, 2017, 174, 803-804.	4.0	1
183	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. Psychiatry Research, 2021, 305, 114194.	1.7	1
184	Question-and-Answer Forum. CNS Spectrums, 2006, 11, 15-16.	0.7	0
185	Effects of the Female Reproductive System on Bipolar Disorder. CNS Spectrums, 2006, 11, 5-6.	0.7	O
186	41 A Modified Delphi Consensus Approach to Clinical Guidelines for Tardive Dyskinesia. CNS Spectrums, 2019, 24, 197-198.	0.7	0
187	Expanding bipolar outreach during college. Journal of Affective Disorders, 2021, 295, 28-32.	2.0	O
188	Sensitive and Personalized Determinations of Likelihood of Being Helped or Harmed. Journal of Clinical Psychiatry, 2017, 78, e554-e554.	1.1	0
189	New Mechanisms, New Opportunities. Journal of Clinical Psychiatry, 2019, 80, .	1.1	O